{
    "clinical_study": {
        "@rank": "116050", 
        "arm_group": [
            {
                "arm_group_label": "Regorafenib (intermittent)", 
                "arm_group_type": "Experimental", 
                "description": "In the Intermittent-Regorafenib arm, regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.\nSubjects in each cohort first receive a single dose of regorafenib (at the assigned dose level) on Pre-cycle Day -14 (\u00b12 days) and an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.\nThe treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.\nCetuximab infusions will be given in a once-weekly dosing-regimen as approved."
            }, 
            {
                "arm_group_label": "Regorafenib (continuous)", 
                "arm_group_type": "Experimental", 
                "description": "In the Continuous-Regorafenib arm, regorafenib will be administered once daily on Days 1-28 of each 28-day Cycle with no break between the cycles. If the starting dose of intermittent-Regorafenib arm in combination with cetuximab was tolerated, the continuous-Regorafenib arm will start with the dose of 100 mg q.d; if the starting dose of the intermittent arm was not tolerated, the dose will start with 60 mg q.d. Subjects in each cohort first receive a single dose of regorafenib (at the assigned dose level) on Pre-cycle Day -14 (\u00b12 days) and an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7. The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1. Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
            }
        ], 
        "brief_summary": {
            "textblock": "To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in\n      combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose\n      (RP2D)"
        }, 
        "brief_title": "Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically or cytologically confirmed, locally advanced or\n             metastatic solid tumors who are not candidates for standard therapy or in whom\n             regorafenib or cetuximab is considered a standard treatment. Patients with metastatic\n             colorectal cancer (mCRC) must have a record of K-ras gene mutational analysis\n             available and no K-ras mutation is present.\n\n          -  Male or female patients \u2265 18 years of age\n\n          -  Women of childbearing potential must have a blood or urine pregnancy test performed a\n             maximum of 7 days before start of study treatment, and a negative result must be\n             documented before start of study treatment\n\n          -  Life expectancy of at least 3 months\n\n          -  Adequate bone marrow, liver and renal function as assessed by the following\n             laboratory requirements conducted within 7 days of starting the study treatment:\n\n               -  Platelet count \u2265 100,000/cubic millimeters (mm3), hemoglobin (Hb) \u2265 8.5 g/dl,\n                  leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) \u2265 1,000/mm3\n\n               -  Total bilirubin \u2264 1.5 x the upper limit of normal (ULN). Mildly elevated total\n                  bilirubin (< 6 mg/dL) is allowed if Gilbert's syndrome is documented.\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 x ULN\n                  (\u2264 5 x ULN for subjects with liver involvement of their cancer)\n\n               -  Alkaline phosphatase limit \u2264 2.5 x ULN (\u2264 5 x ULN for subjects whose cancer\n                  involves their liver).\n\n               -  Amylase and lipase \u2264 1.5 x ULN\n\n               -  Serum creatinine \u2264 1.5 times ULN and creatinine clearance (CLcr) \u2265 30 mL/min\n                  according to the Cockroft-Gault formula\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Prior treatment with Regorafenib\n\n          -  Prior discontinuation of cetuximab treatment due to toxicity or intolerance of\n             cetuximab\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of study medication\n\n          -  Non-healing wound, ulcer, or bone fracture\n\n          -  Systemic anticancer therapy within 28 days\n\n          -  Patients unable to swallow and retain oral medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973868", 
            "org_study_id": "16547"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Regorafenib (intermittent)", 
                    "Regorafenib (continuous)"
                ], 
                "intervention_name": "Regorafenib (Stivarga, BAY73-4506)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Regorafenib (intermittent)", 
                    "Regorafenib (continuous)"
                ], 
                "intervention_name": "Cetuximab (ERBITUX)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Regorafenib", 
            "Cetuximab", 
            "Solid tumors", 
            "Cancer", 
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "MTD is defined as the maximum dose at which the incidence of dose-limiting toxicities (DLTs) during Cycle 1 is below 20 %, or as the maximum dose administered, whichever is achieved first during dose escalation in the Intermittent-Regorafenib arm and/or the Continuous-Regorafenib arm", 
                "measure": "Maximum tolerated dose (MTD) of regorafenib in combination with cetuximab", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Number of participants with Adverse Events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years or longer"
            }, 
            {
                "measure": "Cmax (maximum drug concentration in blood) for regorafenib and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day -14 for regorafenib only and on Day 1 for both"
            }, 
            {
                "measure": "Cmax,md (Cmax after multiple dose) for regorafenib and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "measure": "AUC (area under the blood concentration vs time curve from zero to infinity after single (first) dose) for regorafenib and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 1"
            }, 
            {
                "measure": "AUC(0-24) (AUC from time zero to 24 hours after first-dose administration) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 1"
            }, 
            {
                "measure": "AUC(0-24)md (AUC from time zero to 24 hours after multiple-dose administration) for regorafenib", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "measure": "AUC(0-26)md (AUC from time zero to 26 hours after multiple-dose administration) for cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years or longer"
            }, 
            {
                "measure": "tmax (time to reach maximum drug concentration in blood) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day -14 for regorafenib, M-2, M-5 only and on Day 1 for all"
            }, 
            {
                "measure": "tlast (time of last quantifiable drug concentration) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day -14 for regorafenib, M-2, M-5 only and on Day 1 for all"
            }, 
            {
                "measure": "tmax,md (tmax after multiple-dose administration) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "measure": "tlast,md (tlast after multiple dosing) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "measure": "AUC(0-tlast) (AUC from time zero to the last data point > lower limit of quantification) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day -14 for regorafenib, M-2, M-5 only and on Day 1 for all"
            }, 
            {
                "measure": "AUC(0-tlast)md (AUC(0-tlast) after multiple dosing) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "description": "Day 29 measurements only for participants in regorafenib-Continuous arm", 
                "measure": "AUC(0-24)md (AUC from time zero to 24 hours after multiple-dose administration) for regorafenib and its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15 for M-2, M-5 only and on Day 29 for all, using simulated concentrations only"
            }, 
            {
                "measure": "Cmax for metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day -14 and on Day 1"
            }, 
            {
                "measure": "Cmax,md for metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 15"
            }, 
            {
                "description": "Day 29 measurements only for participants in regorafenib-Continuous arm", 
                "measure": "AUC(0-1)md (AUC from time zero to 1 hours after multiple-dose administration) for cetuximab", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points on Day 29"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}